MedTrace Logo

HeartMate 3 ELEVATE™ Registry

NCT02497950 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2025-03-20

Study results available
· View outcomes & findings →

Summary

Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.

Conditions

Interventions

DEVICE

HeartMate 3

Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3

Sponsors & Collaborators

  • Thoratec Europe Ltd

    collaborator INDUSTRY

  • Thoratec Corporation

    collaborator INDUSTRY

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Finn Gustafsson, MD, PhD · Rigshospitalet, Denmark

  • Jens Garbade, MD, PhD · Gesundheit Nord Klinikverbund Bremen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-13
Primary Completion
2019-02-28
Completion
2022-02-28

Countries

  • Austria
  • Czechia
  • Denmark
  • Germany
  • Israel
  • Italy
  • Kazakhstan
  • Netherlands
  • Poland
  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02497950 on ClinicalTrials.gov